Zacks Research Upgrades Turn Therapeutics (NASDAQ:TTRX) to “Hold”

Turn Therapeutics (NASDAQ:TTRX) was upgraded by analysts at Zacks Research to a “hold” rating in a report released on Tuesday,Zacks.com reports.

TTRX has been the topic of several other research reports. Wall Street Zen upgraded Turn Therapeutics to a “hold” rating in a research note on Saturday, July 18th. D. Boral Capital reissued a “buy” rating and set a $8.00 target price on shares of Turn Therapeutics in a report on Tuesday, March 24th. Weiss Ratings upgraded Turn Therapeutics from a “sell (e)” rating to a “sell (d-)” rating in a research note on Monday, July 13th. Finally, LADENBURG THALM/SH SH raised Turn Therapeutics to a “strong-buy” rating in a report on Monday. One investment analyst has rated the stock with a Strong Buy rating, one has issued a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, Turn Therapeutics currently has a consensus rating of “Moderate Buy” and an average target price of $8.00.

Turn Therapeutics Stock Down 5.5%

TTRX stock opened at $9.62 on Tuesday. The company has a debt-to-equity ratio of 0.97, a current ratio of 2.23 and a quick ratio of 2.23. The stock has a market capitalization of $286.58 million and a P/E ratio of -50.63. Turn Therapeutics has a fifty-two week low of $2.57 and a fifty-two week high of $26.50. The business has a 50-day moving average of $6.70 and a 200-day moving average of $4.81.

Turn Therapeutics (NASDAQ:TTRX) last posted its quarterly earnings data on Monday, May 11th. The company reported ($0.03) earnings per share (EPS) for the quarter. On average, sell-side analysts anticipate that Turn Therapeutics will post -0.09 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Turn Therapeutics

A number of hedge funds and other institutional investors have recently made changes to their positions in TTRX. Composition Wealth LLC acquired a new stake in shares of Turn Therapeutics in the fourth quarter valued at approximately $63,000. HighTower Advisors LLC acquired a new stake in Turn Therapeutics during the fourth quarter worth approximately $78,000. Wellington Shields & Co. LLC acquired a new stake in Turn Therapeutics during the fourth quarter worth approximately $259,000. Geode Capital Management LLC bought a new position in Turn Therapeutics during the 4th quarter worth $68,000. Finally, LPL Financial LLC bought a new position in Turn Therapeutics during the 4th quarter worth $51,000.

Turn Therapeutics Company Profile

We are a pharmaceutical and medical device development company built around a proprietary platform technology designed to enhance drug performance. Our patented mixing process — commercially referred to as PermaFusion™ (“PermaFusion”) — enables stable suspension of polar, water-soluble active pharmaceutical ingredients (“APIs”) in oil-based carriers without the use of emulsifiers. This innovation reduces the quantity of required API inclusion by improving its bioavailability. Reduced API load reduces the likelihood of adverse events.